Supplementary Information

Development of a modularized aptamer targeting the nuclear T-cell suppressor PAC1

Zixi Hu[†], Zhongyu Jiang[†], Zeliang Yang, Liang Liu, Zhenyu Zhu, Yan Jin, and Yuxin Yin^{*}

Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Peking-Tsinghua Center for Life Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing 100191, China.

* Corresponding author.

Institute of Systems Biomedicine, Peking University Health Science Center, Beijing 100191, P.R. China

Phone: (86) 10-8280-5570

Fax: (86) 10-8280-1380

E-mail: yinyuxin@hsc.pku.edu.cn

[†] First authors: These authors contributed equally to the work. Zixi Hu and Zhongyu Jiang



Fig. S1 The incubation ratio of His-tagged PAC1₁₋₁₆₀ protein and Ni-beads was optimized.



Fig. S2 The K_d value of candidate aptamers PA2, PA4, PA5 and PA12.



Fig. S3 Inspected the binding ability of PA5c in different concentrations with P-beads by fluorescence microscopy. Scale bars: 100 μm



Fig. S4 The expression of PAC1 in J-PAC1-Flag cells (A) and J-mCherry-PAC1 cells





Fig. S5 The toxicity of aptamer PAC1-AS-p to Jurkat and Jurkat-PAC1 cells was detected by CCK8 kit.



Fig. S6 Jurkat cells untreated or stimulated with PMA plus ionomycin for 3 h. Mass spectrometry was used to identify the PAC1 interactome after treated with or without PAC1-AS. Then, the GO enrichment analysis up/down-regulated proteins from the data of mass spectrometry. All the target proteins in the GO enrichment analysis were significant (P < 0.05). The abscissa represents the number of enriched proteins.

Round	Dosage	Negative selection		Positive selection			Washin	
	of library (pmol)	Ni- beads (µL)	duration (min)	Protein (µg)	duration (min)	(°C)	g buffer volume (mL)	PCR
1	5000	-	-	60	60	4	1	5
2	1000	-	-	60	60	4	1	7
3	500	-	-	60	60	4	1	7
4	200	5	30	30	60	4	1 × 2	7
5	200	5	40	30	50	4	1 × 2	11
6	200	10	50	30	40	4	1 × 3	7
7	200	10	60	30	30	4	1 × 3	7
8	200	10	60	30	30	4	1 × 3	7

 Table. S1 Conditions used in SELEX.

Name	Sequence 5'-3'	K _d	
PA2	ATCCAGAGTGACGCAGCACCCCACCCGCACG		
	TCATTTCCACCCTTCTCTACTTCTCTCTGGAC	$86\pm25\ nM$	
	ACGGTGGCTTAGT		
PA4	ATCCAGAGTGACGCAGCACCTTACATCCCGC		
	ATACAGCCCGCTCACACCCTCCCTTAGTGGA	110 ± 1 <i>4</i> M	
	CACGGTGGCTTAGT	110 ± 14 IIIVI	
	ATCCAGAGTGACGCAGCACCTACATTCACCG		
PA5	TCTCACTTCTCCCCTCTCGTTCCCCTCTGGAC	(1 + 17 m)	
	ACGGTGGCTTAGT	$01 \pm 1 / \text{ mM}$	
	ATCCAGAGTGACGCAGCAGTGCTCGTGCCCC		
PA12	CGTACCCTTGCTCTAGACCTCTCCCTCTGGAC	93 + 41 nM	
	ACGGTGGCTTAGT		

 Table. S2 Sequences of aptamer candidates.

Name	Sequence 5'-3'
PA5a	ATCCAGAGTGACGCAGCACCTACATTCACCGTCTCAC
(1-58bp)	TTCTCCCCTCTCGTTCCCCTC
PA5b	CCTACATTCACCGTCTCACTTCTCCCCTCTCGTTCCCCT
(19-76bp)	CTGGACACGGTGGCTTAGT
PA5c	CCTACATTCACCGTCTCACTTCTCCCCTCTCGTTCCCCT
(19-58bp)	C
PA5d (25-52bp)	TTCACCGTCTCACTTCTCCCCTCTCGTT

Table. S3 The truncated sequences of PA5.

Name	Sequence 5'-3'
AS1411-L	GCGTTTTCGCGGTGGTGGTGGTGGTGGTGGTGG
PA5c-L	<i>GCGAAAACGC</i> CCTACATTCACCGTCTCACTTCTCCCC TCTCGTTCCCCTC
AS1411-p	<i>GCGTTTTCGC</i> GGTGGTGGTGGTGGTGGTGG*T*G* G
PA5c-p	<i>GCGAAAACGC</i> CCTACATTCACCGTCTCACTTCTCCCC TCTCGTTCCC*C*T*C

Table. S4 Aptamer with artificial bases. (Phosphorodithiate, *)

Name	Sequence 5'-3'
Tnf-F	AACTTGTGTTTCACAGTCCGTTT
<i>Tnf</i> -R	GCCTCCCTCTCATCAGTTCTATG
Gzmb-F	GAGAGGACTTTGTGCTGACTGC
Gzmb-R	GCTGGGTCTTCTCCTGTTCTTTG
<i>Il2-</i> F	CGACCAGAACATCCAGAAGAAT
<i>Il2</i> -R	AGAGACATAAACAGCAGGTCCA
<i>Ifng</i> -F	GGGTTCTCTTGGCTGTTACT
Ifng-R	GAGTTCCATTATCCGCTACATCT
Pac1-F	CAAGAGTATCCCTGTGGAGGAC
Pac1-R	GAAACTGAAGTTGGGGGGAGATG
<i>Pd-1-</i> F	CAGGATGGTTCTTAGACTCCC
<i>Pd-1-</i> R	GCTCATGCGGTACCAGTTTA
Ctla4-F	CAGTGGAAATCAAGTGAACCTC
Ctla4-R	GAGGAGGAAGTCAGAATCTGG
<i>Tim3-</i> F	GGAGCCTCCCTGATATAAATCTAAC
<i>Tim3-</i> R	GCTCCGATGTAGATGCCTATTC
<i>Tigit</i> -F	GCCAGGTTCCAGATTCCATT
Tigit-R	GGATTCTGAGGGCTTTCTTCTT
Gapdh-F	ACCCACTCCTCCACCTTTGA
Gapdh-R	CTGTTGCTGTAGCCAAATTCGT

Table. S5 The sequences of the qRT-PCR primers.